Icon Plc $ICLR Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lessened its holdings in Icon Plc (NASDAQ:ICLR) by 71.4% during the second quarter, Holdings Channel.com reports. The firm owned 1,508 shares of the medical research company’s stock after selling 3,763 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Icon were worth $219,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Whittier Trust Co. raised its position in Icon by 9.2% in the first quarter. Whittier Trust Co. now owns 5,172 shares of the medical research company’s stock worth $905,000 after acquiring an additional 436 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Icon by 36.6% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 1,593 shares of the medical research company’s stock worth $279,000 after purchasing an additional 427 shares during the period. Tributary Capital Management LLC increased its holdings in shares of Icon by 33.6% in the 1st quarter. Tributary Capital Management LLC now owns 5,279 shares of the medical research company’s stock valued at $924,000 after purchasing an additional 1,329 shares in the last quarter. Arkadios Wealth Advisors lifted its stake in shares of Icon by 573.7% in the first quarter. Arkadios Wealth Advisors now owns 7,828 shares of the medical research company’s stock valued at $1,370,000 after purchasing an additional 6,666 shares during the period. Finally, Wealthquest Corp purchased a new stake in Icon during the first quarter worth about $862,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Baird R W raised Icon from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 24th. Mizuho boosted their target price on Icon from $173.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Truist Financial raised their price target on Icon from $187.00 to $234.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Barclays decreased their price objective on shares of Icon from $190.00 to $185.00 and set an “equal weight” rating on the stock in a research report on Friday, October 24th. Finally, Evercore ISI raised their target price on shares of Icon from $170.00 to $240.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $205.00.

Icon Stock Performance

Icon stock opened at $164.36 on Thursday. The stock has a fifty day moving average price of $176.02 and a 200 day moving average price of $160.66. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 52 week low of $125.10 and a 52 week high of $228.29. The firm has a market capitalization of $13.27 billion, a P/E ratio of 22.24, a PEG ratio of 3.04 and a beta of 1.22.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $3.31 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.03. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $1.98 billion. Icon had a net margin of 7.40% and a return on equity of 10.58%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.35 EPS. Equities research analysts anticipate that Icon Plc will post 13.38 earnings per share for the current year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.